Financial
FY2025 revenue €4.07bn (+2.3%); contributive operating margin (CEBIT) 17.9%; net income €398.0m.
Balance sheet figures not captured from release.
HQ France · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2025 revenue €4.07bn (+2.3%); contributive operating margin (CEBIT) 17.9%; net income €398.0m.
Balance sheet figures not captured from release.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | €4.1bn | +2.3% | €728m | €398m | bioMérieux |
Products not yet catalogued.
FY2025 revenue €4.07bn (+2.3%); contributive operating margin (CEBIT) 17.9%; net income €398.0m.
Balance sheet figures not captured from release.
No adverse media involving bioMérieux found in HSH's search of the last 24 months.
No confirmed data breaches, cyber incidents or regulator action involving bioMérieux found in HSH's search of the last 24 months. Unverified claims on ransomware leak-site trackers are not included. NHS DSPT status not yet checked.
Aug 2026: bioMérieux subsidiary BioFire Diagnostics began a Class 2 US recall of specific lots of its BioFire Joint Infection Panel after finding reagent contamination that could cause false positive KPC results.
No notable go-lives, troubled implementations, terminations or customer disputes involving bioMérieux found in HSH's search of the last 24 months.
No competitors linked yet.